Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00645788 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Safety and Efficacy of Ciprofloxacin (Inhaled) in Patients With Cystic Fibrosis
A Phase 2 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 288
- Enrollment target
NCT00645788 is a Phase 2 study that has completed, run by Bayer. The registered enrollment target is 288 participants.
The verdict
NCT00645788, a Phase 2 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 288 participants
- Enrollment target
Study Summary
To evaluate the change in forced expiratory volume (FEV1) from baseline to Day 28-30 between Cipro Inhale-treated and placebo-treated subjects after a 4-week treatment period.
Interventions
- DRUG Placebo
- DRUG Ciprofloxacin (Cipro Inhale, BAYQ3939)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 288 participants |
| Start Date | 2008-05 |
| Est. Completion | 2011-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00645788
The ClinicalTrials.gov registry entry for NCT00645788 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 288 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00645788 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00645788 about?
NCT00645788 is a clinical study titled "Study to Evaluate the Safety and Efficacy of Ciprofloxacin (Inhaled) in Patients With Cystic Fibrosis". To evaluate the change in forced expiratory volume (FEV1) from baseline to Day 28-30 between Cipro Inhale-treated and placebo-treated subjects after a 4-week treatment period.
What is the current status of trial NCT00645788?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 288 participants. The study started on 2008-05. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00645788?
The interventions under investigation include: Placebo (DRUG), Ciprofloxacin (Cipro Inhale, BAYQ3939) (DRUG).
Who is sponsoring clinical trial NCT00645788?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.